FLT3 and acute myeloid leukemia: In particular, the co-occurrence of FLT3-ITD and FLT3-TKD mutations within the same subclone of an individual patient with AML (1–2% of patients at diagnosis) may confer primary resistance to several FLT3 inhibitors (Figure 1).